Teva CEO steps down; Mylan to pay $96.5 million to settle pay-for-delay claims; Merck files Keytruda with the FDA for bladder cancer
The bill, if enacted, would publicly share information about industry payments to physician assistants and nurse practitioners.
Novo Nordisk CEO describes 'volatile' pricing environment; Lilly to cut 200 research and development jobs; pharma opts out of Super Bowl this year
Pharmaceutical and healthcare companies use a mix of corporate and brand accounts on Instagram, and some are turning to celebrity influencers.
Trial finds that Repatha reduces risk of heart attack and stroke; California measure would ban drug coupons in some cases; Takeda to limit price increases
Thirty-percent of Keytruda's U.S. sales came from its lung-cancer indication.
To drive the point home, the ads even feature an image of an actual case of shingles. The blistering red rash appears on-screen for several seconds.
Biogen completes hemophilia spinoff; old drug being tested as a prostate cancer treatment; Merck reports Q4 decline in revenue
A bout with Lyme disease led Yee to found a company that helps patients measure and track their breathing patterns.
A WPP insider has been tapped as CEO of WPP Health & Wellness, and Ogilvy CommonHealth chairman/CEO Matt Giegerich is stepping down.
Trump wants to speed up drug approvals; Sanofi allergy drug gets OTC approval; Lilly ends final solanezumab trial
Merck and Aetna partner in value-based drug pricing; data scientists rising in the biopharma ranks; Japanese pharma leads digital health innovation
WPP will create "Team WBA," a bespoke team that would work on traditional and digital advertising, media, and PR.
The annual awards program has added three new categories.
The drugmaker previously launched an unbranded campaign about lung-cancer biomarkers.
Diabetes patients sue drugmakers over price increases; the FTC opens Mylan investigation; Fitbit to ramp up marketing
Merck details price increases for its drugs; Trump's call to freeze federal hiring may not affect the FDA; Sanofi to settle vaccines-pricing lawsuit
BMS cuts forecast after Opdivo setbacks; diabetes death rate rises; McKesson acquires prior authorization startup
A new survey found that 34% of healthcare and pharma marketers say that the election of President Trump will not affect their marketing budgets.
A Haymarket Media survey of more than 700 client-side marcomms execs in the US reveals the shift in power will not significantly affect budgets.
J&J to buy Actelion for $30 billion; Pfizer fights advertising ban related to Advil; almost half of women with breast cancer report severe side effects
Transportation barriers can limit patient involvement in clinical trials.
Docs said patients asked about drugs from DTC ads six times in a typical week, compared to just twice a week five years ago.
Novartis forecasts slower growth in 2017; Actelion reports trial failure for PAH drug; HHS nominee Tom Price denies conflict of interest claims
Endo settles pay-for-delay charges; Trump signs order withdrawing U.S. from TPP; administration considers Patrick Soon-Shiong for healthcare role
But it may also increase the reporting burden for drugmakers.
BMS and Ono settle Keytruda patent suit; PhRMA plans to release new campaign; Trump moves forward with plans to scale back the ACA
How the retail pharmacy chain uses customer data to make its marketing messages relevant.
Many healthcare comms leaders are paying close attention to the debate between "access" to healthcare versus making it a requirement, experts say.
Pharma among top sponsors of Trump inauguration parties; AstraZeneca exec to replace GSK president of global pharmaceuticals; EpiPen rival to relaunch
The regulator is providing examples of appropriate off-label communications.
The FDA releases three documents; PBM rebates eating into drugmaker revenue: PhRMA; most oncologists on Twitter receive money from pharma
Deborah Furey will lead the agency's pilot of a new personalized marketing offering.
MM&M last year named its inaugural class of 16 Femmes and 20 Women to Watch. Who should be considered for this year's list of breakthough women?
Rep. Price to answer questions at confirmation hearing; 22 drugmakers invest in fighting disease in poor countries; FDA approves generic of Jazz's Xyrem
Endo hires new head of U.S. branded pharma, and three other people moves for you to know about.
The agency issued 11 enforcement letters last year.
Biogen to pay $1.25 billion for patents to MS drugs; Supreme Court to hear Novartis case over Zarxio delay; Merck KGaA inks big-data deal
CVS to sell generic EpiPen; FDA finalizes biosimilar naming rules; Pfizer wants to make a deal
The firm is sharing space in the City of Brotherly Love with healthcare media shop CMI.
There are dozens of players, including leaders like IBM Watson Health and Verily as well as smaller concerns, lining up to sell pharma access to some sort of data solution.
Trump says pharma is "getting away with murder"; Senate majority votes to repeal ACA; IBM Watson Health and FDA to study blockchain technology
Merck said the FDA accepted its submission of a Keytruda/chemotherapy combo drug and granted it Priority Review.
J&J's CEO may be right. Customers of all kinds are demanding change.
The FDA accepts Keytruda combo for review; Valeant offloads Dendreon and skincare brands; pharmacies feeling the squeeze from Express Scripts
DeViteri started in the newly created role this month.
The American College of Physicians said the costs of some new diabetes drugs do not always mean added benefits for patients.
The questions being asked about how drugs are priced are weighing heavily on pharma leaders, and they know the issue is not going away.
Illumina and IBM enter DNA sequencing partnership; J&J to outline price increases in new report; Egalet's opioid Arymo ER gets FDA approval
The new agency will focus on marketing goods and services to people 50 years of age and older.
She says her experience in consumer brands helps her push healthcare clients to be more creative.
Takeda to acquire Ariad for $4.6 billion, Merck pairs with Incyte for Keytruda combo drug collaboration; Sanofi announces autoimmune research deal
Judge halts Praluent sales; clinical-trial data for Diclegis in question; cancer drugs to make up larger portion of total drug spending
The agency has faced questions about how it regulates off-label communications.
Orexigen launches new campaign for weight-loss drug Contrave; Arena sells Belviq to Eisai; Alexion reportedly pushed for 'pull-in' sales
The merger of Quintiles and IMS Health closed in October.
Sanofi, Regeneron denied bid to overturn Amgen win in patent case; Abbott to close St. Jude deal; Gilead hires SVP of hematology and oncology
With 2016 in the rearview, here are four stats detailing how the FDA fared last year in enforcing regulations and approving new drugs.
Facebook and Instagram are the primary location for brands to engage with online tribes, while Raptr and PlayFire are a hit with boomers.
The FDA approves 22 new drugs in 2016; the Philippines orders Sanofi to stop Dengvaxia ads; new spinal muscular atrophy drug to cost $375,000
Gilead forms network to encourage access to hep.-C drugs; Dentsu CEO to resign following the suicide of a staffer; BI to divest animal-health products
We at MM&M found out just how much pharma marketers love a list. Here, read through the year's most-read technology stories.
Sanofi sues Novo over Tresiba marketing; the FDA issues two more untitled letters; U.S. health spending rose substantially from 1996 to 2013
Find out what stories generated the most interest among our readers.
Allergan's board endorses its social contract with patients; drugmakers that market painkillers are hiring DEA officials; the FDA approves new Biogen drug
When the vision company needed to demonstrate to parents the plight of children struggling to see, it turned to Olson 1to1 and a 360 video to tell the story.
Senate report said certain drugmakers act like hedge funds; ViiV to develop HIV prevention drug; lawmakers to replace ACA with "universal access"
GSK's two-drug combo for HIV has positive Phase-III results; the FDA approves glucose system that doesn't use finger pricking; Rite Aid to sell stores
The agency has sent nine untitled and warning letters so far this year.
A recent CME course using Facebook Live generated 34,000 views and 600 comments.
Biogen names new CEO; the FDA issues two warning letters; Allergan to acquire aesthetics firm
For years pharma has said it needs to be more focused on patients, has it delivered?
The FDA drops Chantix's black-box warning; hospitals try to reduce drug spending; AstraZeneca's head of oncology to depart
MM&M conducted Q&As with Stephanie Robinson, senior account manager, The Bloc; Jessica Hill, account supervisor, Ogilvy CommonHealth; and Austin Bald, account executive, TBWA\WorldHealth.
Read what they have to say about the defining moments and challenges in their careers.
Many young staffers agree one of the biggest challenges in their careers has been learning the delicate balance of when to speak up and when to listen.
We are looking for young professionals who are determined to develop their careers in healthcare advertising and marketing.
Allergan to settle allegations relating to speakers bureaus; Mylan launches generic version of the EpiPen; 20 states sue six drugmakers accused of price-fixing
The connection to Pristiq is not overt in the app's user interface, though Moodivator is featured on Pristiq's website.
Drugmakers promote new type of opioid with unproven results; Heritage execs charged for price-fixing generics; Pershing sells more Valeant shares
Regulators said the ads distract viewers from superimposed safety information.
The previous deadline was January 9.
Obama signs 21st Century Cures Act into law; the FDA approved 19 new drugs in 2016; Sanofi in talks to acquire Actelion
Eli Lilly partnered with Express Scripts to improve adherence for diabetes patients with high-deductible health plans.
Lilly to offer discounts for insulin products; Trump reportedly considering Scott Gottlieb to lead FDA; three execs depart Valeant
Bob Chandler retired from his role as cofounder and principal of Chandler Chicco Companies and president of InVentiv Health Communications in 2014.
TV actress Jamie Lynn Sigler shares her experience using the multiple-sclerosis drug in the branded campaign.
Generic Tamiflu estimated to generate $500 million in savings this year; ADA expected to launch new diabetes treatment guidelines; Alexion CEO resigns
It is also seeking industry input for a new category of honoree, the Top 10 Innovation Catalysts.
On the heels of Keytruda's approval in first-line lung cancer, the drugmaker kicked off an unbranded campaign raising awareness about biomarkers.
BMS to pay $19.5 million to settle marketing violations for Abilify; AstraZeneca to cut 700 U.S. jobs; Trump reportedly considering Jim O'Neill to lead FDA
The risk of fraud is also very real, especially in an industry that already faces privacy and compliance challenges, one expert says.
A California lawmaker reintroduces drug-pricing bill; France, Poland, Spain, and Sweden lobby to host EMA; drug stocks fall after Trump's comments
Pharma can reach physicians within the EHR, but they must send the right message at the right time, she said at an MM&M event.
Wilson will succeed founder and CEO John Seng.
This is W2O Group's third acquisition since a private-equity firm took an investment in May.
The bill now heads to President Obama's desk. He is expected to sign the sweeping piece of legislation.
Trump puts pharma on notice over drug prices; Mylan lays off nearly 10% of its workforce; Pfizer slapped with U.K. antitrust fine
The drugmaker is using Propeller Health's sensor technology to find new ways to improve adherence in clinical studies.
Boehringer Ingelheim and Eli Lilly have to position their third-in-class diabetes medication Jardiance as a heart drug.
- Top 25 rare disease brands, by sales
- Five things for pharma marketers to know: Monday, February 13, 2016
- Merck's DTC ad for Keytruda hints at more cancer brands turning to TV
- Five things for pharma marketers to know: Thursday, February 16, 2017
- Five things for pharma marketers to know: Wednesday, February 15, 2017